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Abstract
Introduction
The US Public Health Service urges providers to screen 
patients  for  smoking  and  advise  smokers  to  quit.  Yet, 
these  practices  are  not  widely  implemented  in  clinical 
practice. This study provides national estimates of sys-
tems-level  strategies  used  by  private  health  insurance 
plans to influence provider delivery of smoking cessation 
activities.
Methods
Data  are  from  a  nationally  representative  survey  of 
health plans for benefit year 2003, across product types 
offered by insurers, including health maintenance orga-
nizations (HMOs), preferred provider organizations, and 
point-of-service products, regarding alcohol, tobacco, drug, 
and  mental  health  services.  Executive  directors  of  368 
health plans responded to the administrative module (83% 
response rate). Medical directors of 347 of those health 
plans, representing 771 products, completed the clinical 
module  in  which  health  plan  respondents  were  asked 
about screening for smoking, guideline distribution, and 
incentives for guideline adherence.
Results
Only 9% of products require, and 12% verify, that pri-
mary  care  providers  (PCPs)  screen  for  smoking.  HMOs 
are more likely than other product types to require screen-
ing. Only 17% of products distribute smoking cessation 
guidelines to PCPs, and HMOs are more likely to do this. 
Feedback to PCPs was most frequently used to encourage 
guideline adherence; financial incentives were rarely used. 
Furthermore,  health  plans  that  did  require  screening 
often conducted other cessation activities.
Conclusion
Few private health plans have adopted techniques to 
encourage the use of smoking cessation activities by their 
providers.  Increasing  health  plan  involvement  is  neces-
sary to reduce tobacco use and concomitant disease in the 
United States.
Introduction
Tobacco use is a leading preventable cause of death 
and  extensive  health-related  economic  losses  (1). 
Tobacco  use  cessation  efforts  are  highlighted  by  the 
2008 US Public Health Service smoking cessation clini-
cal practice guideline (2). Effective treatments exist, and 
providers influence smoking cessation rates when they 
encourage their patients to quit smoking (2), which is 
recommended for quality care delivery (3). Yet, a large 
gap  is  found  between  the  existence  of  guidelines  and 
recommendations and their implementation in clinical 
practice (4,5).
The  clinical  practice  guideline  emphasizes  the  need 
for systems-level approaches that can increase provider 
intervention and reduce smoking (2,6). It calls on adminis-
trators, insurers, and purchasers to provide leadership in 
implementing systems interventions that include provider 
training,  resources,  and  feedback.  It  also  recommends 
insurance  coverage  and  physician  reimbursement  for 
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tobacco dependence treatment (2). Such systems interven-
tions are necessary for preventive medicine and chronic 
disease management (7).
Health plans, which offer specific products or pack-
ages  of  defined  benefits  to  their  purchasers  (8,9), 
may  be  influenced  to  adopt  systems-level  strategies. 
Purchaser demand often drives what is covered by those 
products, and purchasers can ensure specific activities 
by requiring them in the contract, although they usu-
ally do not demand smoking cessation services (10,11). 
Additionally,  screening  activities  can  be  considered 
a basic indicator of the quality of the health plan, as 
indicated  by  inclusion  of  measures  of  medical  assis-
tance  with  smoking  cessation  —  advising  smokers  to 
quit, discussing medications, and discussing strategies 
— in the National Committee for Quality Assurance’s 
Healthcare  Effectiveness  Data  and  Information  Set 
(HEDIS)  accreditation  measures  (12,13).  The  HEDIS 
measures may be an incentive to health plans to offer 
screening, cessation advice, and referral.
Health plans, in turn, may influence the behaviors of 
providers  and  enrollees.  About  60%  of  Americans  have 
employer-based  health  insurance,  largely  through  man-
aged  care  organizations  (14,15).  Twenty  percent  of  pri-
vately  insured  adults  are  current  smokers  (16).  Thus, 
private health plans have an important role for adoption 
and  implementation  of  clinical  practice  guidelines.  By 
implementing  systems-level  changes,  health  plans  can 
influence providers to help their patients quit smoking. In 
addition, health plans have been shown to independently 
influence HEDIS quality measures, beyond actions of pro-
viders,  for  patients  across  multiple  health  maintenance 
organizations and provider groups (17).
We used a nationally representative survey of health 
plans to examine systems-level strategies for smoking ces-
sation,  considering  screening  and  guideline  distribution 
practices in particular, across a full product range offered 
by private health plans (health maintenance organizations 
[HMOs],  point-of-service  [POS]  products,  and  preferred 
provider organizations [PPOs]). Prior studies have exam-
ined  provider  activities  or  patient  knowledge  or  receipt 
of services, excluded some types of health plans, or were 
not nationally representative (4,6,7,10,18-22). We investi-
gated how health plans are implementing systems-level 
approaches to smoking cessation.
Methods
Data source and sample
We conducted a nationally representative telephone sur-
vey of 368 private health insurance companies in 60 mar-
ket areas for benefit year 2003 (23). The aim of the overall 
study was to understand how private health plans provide 
alcohol, drug, and mental health services, and how this 
has changed over time. These data, collected periodically 
by our team, are the most recent nationally representa-
tive data available about alcohol, drug, and mental health 
services in private health plans. The Brandeis University 
institutional review board approved the study.
The study used the sampling frame from the Community 
Tracking  Study,  a  longitudinal  study  of  health  system 
changes and their effects on people (24). The primary sam-
pling units for this study were the 60 Community Tracking 
Study market areas selected to be nationally representa-
tive; health plans were then selected within market areas. 
Plans serving multiple markets were defined as separate 
health plans for the study to ensure that a market area 
was fully characterized; data were collected with reference 
to the specific market area. At each health plan, we asked 
respondents about the top 3 products they offered, defined 
as “packages, plans, or contracts that are similar in terms 
of  out-of-network  coverage,  referrals,  and  primary  care 
physicians.”  For  each  product,  we  asked  respondents 
about the “most commonly purchased package.”
To be eligible, a health plan had to offer a managed care 
product in the market area, have at least 300 subscrib-
ers or 600 covered lives in the market area, not function 
exclusively  as  a  third-party  administrator,  and  have  at 
least 1 eligible product. Eligibility for a product within the 
health plan included having at least 100 subscribers or 
200 covered lives in the market area, not enrolling exclu-
sively Medicaid or Medicare patients, being sold directly 
to  purchasers  such  as  employers,  not  being  exclusively 
a third-party administrator product for the health plan,   
being a managed care product or consumer-driven health 
plan, and offering coverage for a full range of health and 
behavioral health services.
The sample totaled 814 plans, of which 441 were deemed 
eligible. Ineligible plans had closed, merged, or were oth-
erwise unreachable (n = 146); did not offer comprehensive 
health care products (n = 106); had low enrollment (n = VOLUME 8: NO. 1
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76); or were ineligible for several other reasons (n = 45). Of 
eligible plans, 368 (83%) responded to the administrative 
module, reporting on 812 products. Of responding plans, 
347 (79% of eligible health plans, and 94% of health plans 
completing the administrative module) completed the clin-
ical module, reporting on 771 products. Nonrespondents 
were more likely to offer HMO products. Four consumer-
driven plans, which allow enrollees to design their own 
network and benefit options, were excluded from analyses 
because they represent a very different approach than the 
other product types, and few existed.
The survey focused on alcohol, drug, and mental health 
services; several questions were about smoking cessation 
in primary care settings. It had an administrative module 
addressing  behavioral  health  contracting,  benefits,  net-
work management, and provider payment, and a clinical 
module addressing primary care screening and treatment, 
specialty  treatment,  utilization  management,  prescrip-
tion drugs, and quality improvement. The administrative 
and  clinical  modules  were  conducted  sequentially,  took 
about 45 minutes each to complete, and collected detailed   
product-level  data  for  each  topic.  Typically  the  health 
plan’s executive director responded to the administrative 
module and referred us to the medical director to com-
plete the clinical module. In some cases, the health plan 
requested that the managed behavioral health organiza-
tion, with which plans sometimes contracted to provide 
alcohol, drug, and mental health services, provide infor-
mation for the clinical module. Data were collected from 
April 2003 through April 2004.
Health plan products were classified by product type: 
HMOs, in which services are provided by a network of 
affiliated providers, and services outside the network are 
generally  not  covered;  POS  products,  in  which  both  in- 
network or out-of-network services may be chosen, albeit 
with  different  coinsurance  payments  or  deductibles;  or 
PPOs, in which enrollees are given a financial incentive, 
usually a different coinsurance payment or deductible, to 
use a preferred network of providers.
Measures
The clinical module, typically answered by the health 
plan’s (or managed behavioral health organization’s) medi-
cal director, included a series of questions related to smok-
ing,  which  allowed  consideration  of  select  systems-level 
smoking  activities  as  implemented  by  the  health  plan. 
The first set of questions focused on screening for smoking:   
1) Were primary care providers (PCPs, which include phy-
sicians, nurses, and other physician extenders) required 
by the health plan to screen for smoking among at least 
some  of  their  patients?  2)  Were  PCPs  required  by  the 
health plan to use a general health screening question-
naire that included questions about smoking? and 3) Did 
the health plan verify that screening for smoking was done 
by PCPs, and if so, was there a system to report the results 
of that screening? The second set of questions focused on 
written guidelines for smoking: Did health plans distrib-
ute written guidelines specifically for primary care treat-
ment of smoking? If so, which techniques were used by the 
health plan to encourage PCPs to adhere to the guidelines: 
financial incentives, training about guidelines, feedback 
regarding their own performance relative to guidelines, or 
feedback about guideline adherence by network providers 
overall? Specific survey items used in these analyses may 
be found in the Appendix.
Statistical analysis
We  analyzed  data  with  SUDAAN  version  9.0  (RTI 
International,  Research  Triangle  Park,  North  Carolina) 
for sampling variance estimation, given the complex sam-
pling design. The reported findings are national estimates, 
weighted to be representative of health plans’ private man-
aged care products in the continental United States. The 
sampling weights applied to produce national estimates 
were computed from the inverse of the selection probabili-
ties, which were computed from each stage of selection: site 
selection (exactly the probability used in the Community 
Tracking Study) and the selection of the plans in each site. 
Nonresponse adjustment and iterative proportional fitting 
were used to calculate the final weights. We used pairwise 
t  tests  to  determine  significance  of  screening  behaviors 
for each product type (Table) and whether screening was 
required; health plans with missing data were excluded 
only from the specific analysis in which those data were 
missing (ie, exclusions did not occur listwise).
Item response rate
The  item  response  to  several  smoking  questions  was 
lower  than  for  other  questions  in  the  clinical  module. 
Smoking  is  often  considered  a  general  medical  rather 
than a behavioral health concern, so some respondents to 
this survey about behavioral health services may not have 
known about more general smoking-related activities in VOLUME 8: NO. 1
JANUARY 2011
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the health plan. This situation would be most likely when 
the managed behavioral health organization was asked to 
respond.
Results
Health  plans  were  split  fairly  evenly  among  product 
types; slightly fewer identified their products as HMOs 
(29%) than POS products (36%) or PPOs (35%). Nearly 
three-fourths of products were in health plans that con-
tracted  with  a  managed  behavioral  health  organization 
for their alcohol, drug, and mental health services. Most 
(86%) plans were for-profit.
Screening for smoking
Few products require screening for smoking in primary 
care settings (Table). Only 9% require that PCPs screen 
for smoking among at least some clients. Slightly more 
products  require  the  use  of  a  general  health  screening 
questionnaire that includes smoking (11%) or verify that 
PCPs screen for smoking (12%). If they do verify screening, 
most have a system in place to report those results.
While screening activities for smoking are low overall, 
HMOs are more likely than either POS or PPO products 
to require screening among at least some patients (15%), 
require screening via a general questionnaire (17%), and 
verify that screening is conducted (19%). However, if they 
verify that screening is conducted, HMOs are less likely 
than other products to have a system in place to report 
the results.
Distribution of written smoking cessation guidelines
More products report distributing guidelines than requir-
ing  screening,  although  the  proportion  is  low  (Table). 
Overall, only 17% of products distribute smoking cessa-
tion guidelines specific to primary care. As with screening, 
HMOs are more likely to do this; 24% distribute guide-
lines, compared with 12% of POS products and 16% of 
PPO products.
If guidelines are distributed, a variety of techniques may 
be used to encourage adherence to them (Table). Few prod-
ucts offer financial incentives to PCPs. Nearly one-third of 
products overall offer training on guidelines, and only one-
fifth of PPO products do. The most frequently used tool to 
encourage adherence to guidelines was feedback to PCPs. 
Of products that distributed written guidelines, 37% pro-
vided feedback regarding the provider’s own performance 
and more than half (53%) provided feedback about overall 
network provider adherence to guidelines.
Multiple screening activities
Products  that  require  screening  for  smoking  among 
at least some patients are also significantly more likely 
than those that do not require screening to conduct other 
screening  and  distribution  activities.  Among  those  that 
require screening, 51% to 62% also require screening in 
a  general  health  questionnaire,  verify  that  screening  is 
done, or distribute written guidelines, while less than 11% 
of those that do not require screening conduct these same 
activities. Thus, participation in 1 activity is associated 
with increased participation in the others.
Discussion
Systems-level  support  for  smoking  cessation  is  not 
widespread among private health plans. Despite current 
clinical guidelines and recommendations, most plans do 
not  require  providers  to  screen  for  smoking,  determine 
whether screening is done, or distribute relevant guide-
lines to providers.
Some studies based on enrollee reports have found high 
rates  of  identifying  smokers  (10,13,21),  but  our  results 
based on health plans are consistent with a 2001 survey of 
physician organizations, which found few physicians are 
required to provide smoking cessation activities, and very 
few  receive  financial  incentives  from  health  plans  (25). 
America’s Health Insurance Plans reports that two-thirds 
of health plans have written guidelines for smoking cessa-
tion (10), but we found that few actually distribute them. 
The positive news from our study is that health plans that 
make an effort to screen for smoking report multiple smok-
ing cessation activities, an indication of a multipronged 
approach to improve smoking cessation rates. Such a sys-
temic approach is likely to improve provider behavior.
When  techniques  were  used  to  encourage  adherence 
to guidelines, we found that plans most often compared 
results  among  providers,  but  financial  incentives  were 
rarely used; this was similar to other findings (10). In other 
research, both provider feedback and financial incentives VOLUME 8: NO. 1
JANUARY 2011
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were related to significantly more smoking cessation activi-
ties reported by patients, and greater knowledge of and 
assistance in these activities by providers (25-27). Health 
plans that increase use of these techniques may improve 
their enrollees’ smoking rates. However, even when health 
plans  use  some  of  these  techniques,  providers  may  be 
unaware of them, indicating room to improve adoption and 
implementation (28). Health plans could also step beyond 
the  provider  to  offer,  for  example,  incentives  directly  to 
enrollees, online smoking cessation programs, or programs 
within a broader wellness approach.
Why are health plans not doing more in this arena, when 
it has been shown that health plan strategies can inde-
pendently  affect  activities  such  as  screening  (17)?  Lack 
of provider compliance is cited as a barrier to increased 
activities  by  health  plans  (10).  We  found  that  slightly 
more health plans verify screening than require screen-
ing, perhaps in response to this perceived barrier of poor 
compliance. Moreover, a health plan requirement may be 
considered a burden for providers (14) or not realistically 
enforceable. Health plans also report specific systems-level 
barriers to addressing smoking cessation, including com-
peting priorities, issues with data and reporting systems, 
and lack of resources, staffing, or funding (10,29). Health 
plans may assume that responsibility lies elsewhere, such 
as with providers or the public health system, despite the 
call  for  systems-level  approaches  that  include  insurers 
(2). Purchasers largely do not demand smoking cessation 
interventions as part of their health care packages (10,11), 
yet  purchaser  demand  can  drive  health  plan  activities. 
Health plans may doubt the business case for smoking 
cessation activities: 61% of plans report delayed return on 
investment as a barrier (10). Yet, the literature suggests 
that tobacco use cessation activities are cost-effective for 
both health plans and employers and provide a reasonable 
return on investment (2,30,31).
Despite overall low rates of required screening for smok-
ing  and  distribution  of  written  guidelines,  HMOs  were 
significantly  more  likely  than  other  products  to  report 
each activity. The original HMO mission often highlighted 
prevention  as  well  as  treatment  (32,33);  thus,  smoking 
cessation activities may fit better there than in other types 
of health plans. It is also perhaps easier to conduct these 
activities  within  the  constraints  of  the  more  managed 
provider network used by most HMOs. That is, HMO pro-
viders might be more aware of the health plan rules and 
guidelines compared with providers in a loosely networked 
PPO  who  participate  in  multiple  health  plans.  HMOs 
may also be more likely to emphasize smoking cessation 
activities because they are measured as part of HEDIS 
(12) and thus may be viewed as valuable to accreditation; 
HEDIS did not apply to PPOs at the time of the survey. 
In 2003, HEDIS showed that 69% of smokers who saw a 
physician  were  advised  to  quit,  yet  only  36%  discussed 
specific strategies with their physician (13). Although not 
directly comparable to our findings of health plan activi-
ties, because they are ascertained via enrollee surveys and 
do not identify the systemic approaches that health plans 
may use, HEDIS measures may improve with a systems 
focus on smoking cessation by health plans.
We note several potential limitations. First, this survey 
focused on alcohol, drug, and mental health services and 
may have been completed by someone more familiar with 
these services and less familiar with general medical ser-
vices, such as a representative of a separately contracted 
managed behavioral health organization. If smoking cessa-
tion is in the purview of general medical services (ie, those 
provided by PCPs) then some respondents may not have 
been  aware  of  those  activities,  as  indicated  by  missing 
data, and we have potentially underestimated the preva-
lence of cessation activities. However, even if all missing 
data had been a positive response, the prevalence of smok-
ing cessation activities by health plans would still be low. 
Second, this is a survey of health plans, not providers, so 
it is unknown how successfully providers in these plans 
are screening their patients and how this varies by health 
plan requirements. Third, although these data from 2003 
are still the most recently available about health plans, 
changes over time may have occurred. Fourth, screening 
is only the first step in a range of recommendations that 
lead to smoking cessation.
Even  if  all  health  plans  required  screening,  verified 
that  their  providers  did  it,  and  distributed  treatment 
guidelines,  health  plans  should  encourage  and  monitor 
smoking  cessation  activities  and  follow-up  (29),  moving 
beyond calls for improved delivery of services by providers 
(34,35). Such activities could include requiring that pro-
viders not only ask their patients whether they smoke but 
also advise them to quit and then provide assistance with 
quitting  through  either  medication  or  quitline  services. 
Health plans should pay for smoking cessation services, 
which is an incentive to providers to offer them. Billing 
codes specific to tobacco cessation counseling were added 
to the Healthcare Common Procedure Coding System in VOLUME 8: NO. 1
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2005 and Current Procedural Terminology in 2008. The 
addition of the codes to these standard billing code sys-
tems used by insurers and providers allows providers to 
be paid for smoking cessation services and gives plans a 
way to indicate their coverage of these services. However, 
it is unclear how many health plans accept these codes for 
reimbursement. Unless the codes are adopted across plans, 
providers, who largely accept multiple types of insurance 
and may not know the insurer for any given patient (34), 
may be unlikely to use the codes and to offer smoking ces-
sation services for which they are not reimbursed.
These data from the 2003 benefit year, the most recently 
available  national  data  on  private  health  plans,  are 
still relevant to consider how systems-level interventions 
can affect providers’ ability to change behavior in their 
patients. Our findings of limited systems-level efforts by 
health plans to promote smoking cessation activities by 
their providers suggest several conclusions. First, systems 
approaches to smoking cessation still need to be enhanced 
and  adopted  (2,18,36).  Second,  purchasers  and  partici-
pants  need  to  demand  systems-level  smoking  cessation 
activities (35). Third, research should investigate effective 
incentives and techniques that health plans could use to 
change behavior among providers and enrollees. Fourth, 
a variety of smoking cessation strategies, as highlighted 
by Orleans (35), should continue to be encouraged. Future 
research should consider how health plan activities inter-
act  with  activities  of  other  systems,  such  as  the  public 
health system, and of providers themselves. It should also 
address health plans’ concern with return on investment 
as a barrier to these activities (34). In the meantime, by 
encouraging health plans to focus on smoking cessation at 
the systems level, further inroads can be made to reduce 
the burden of smoking on enrollees, employers, and health 
plans themselves.
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Table
Table. Screening Activities for Smoking and Written Guidelines for Smoking Cessation in a National Survey of Private Health Plans, 
2003a
Screening Activities
Product Type, No. (%) P Valueb
All, n = 767, 
Weighted n = 
7,530
HMO, n = 247, 
Weighted n = 
2,209
POS, n = 261, 
Weighted n = 
2,702
PPO, n = 259, 
Weighted n = 
2,619 HMO vs POS HMO vs PPO POS vs PPO
PCPs required to screen 
for smoking among some 
patientsc
632 (9) 308 (1) 1 () 1 (6) .003 <.001 .
PCPs required to use 
general health screen-
ing questionnaires that 
include smokingd
68 (11) 306 (1) 18 (8) 191 (9) .003 .001 .1
Verify that PCPs screen for 
smokinge
816 (12) 392 (19) 28 (11) 16 () .009 <.001 .2
Have system to report 
results of verification
696 (8) 318 (81) 21 (86) 13 (9) .31 .02 .32
Written smoking cessa-
tion guidelines for primary 
care treatment are dis-
tributedf
1,009 (1) 32 (2) 28 (12) 298 (16) <.001 .002 .08
If guidelines are distributed, following are given to PCPs to encourage their use:
Financial incentivesg 60 (6)  (2) 3 (19) 0 .29 .23 .2
Training about guidelinesh 29 (31) 10 (3) 8 (31) 60 (22) .8 .02 .26
Feedback about PCPs’ 
performance relative to 
guidelinesi
29 (3) 11 (3) 12 (6) 6 (28) . .0 .18
Feedback about general 
network provider adher-
ence to guidelinesj
11 (3) 1 (6) 16 (61) 2 (39) .6 .0 .06
 
Abbreviations: HMO, health maintenance organization; POS, point-of-service product; PPO, preferred provider organization; PCP, primary care provider. 
a Products are defined as packages, plans, or contracts that are similar in terms of out-of-network coverage, referrals, and PCPs within a given health plan. 
Reported percentages exclude products for which data were missing; all data are weighted. 
b Calculated by using pairwise t tests. 
c Missing % (n = 32) of products (HMO n = 12, POS n = 83, PPO n = 162). 
d Missing 1% (n = 1,292) of products (HMO n = 09, POS n = 30, PPO n = 13). 
e Missing 9% (n = 690) of products (HMO n = 129, POS n = 9, PPO n = 6). 
f Missing 20% (n = 1,06) of products (HMO n = 31, POS n = 33, PPO n = 82). 
g Missing 1% (n = 6) of products (HMO n = 6, POS n = 0, PPO n = 0). 
h Missing % (n = 9) of products (HMO n = 22 , POS n = 6, PPO n = 21). 
i Missing 20% (n = 211) of products (HMO n = 106, POS n = 6, PPO n = 99). 
j Missing 2% (n = 23) of products (HMO n = 11, POS n = 6, PPO n = 11).VOLUME 8: NO. 1
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Appendix. Selected Survey Questions 
Regarding Systems-Level Smoking 
Cessation Activities
1. And what type of product would you say [PRODUCT NAME] is? Is it an 
HMO, PPO, POS, indemnity product, a consumer-driven plan, or is it some-
thing else?
PROBE: Please select the product type that most closely resembles 
[PRODUCT] in terms of out-of-network coverage and referrals. IF NEEDED, 
READ DEFINITIONS.
.1 First I’m going to ask about screening and treatment for mental health, 
alcohol and drug problems, and smoking in [SITE].
Under [PRODUCT], do you check to see if screening is done by primary care 
practitioners for any of the following?
PROBE: “Screening” is defined as the identification of a problem in patients 
who are not yet known to have it.
PROBE: If you check whether screening is done, but only for a subset of pro-
viders, eg, high-volume providers, please indicate “Yes, some PCPs.”
PROBE: Primary care practitioners can include physicians as well as nurses 
or other physician extenders.
a.  Mental health problems such as major depression or anxiety disorder
b.  Alcohol problems
c.  Drug abuse problems
d.  Smoking
. Now we are going to ask about screening that the health plan requires in 
primary care settings. We begin with questions about general health screen-
ing and then turn to screening for specific mental health problems, alcohol 
and drug abuse, or smoking.
Under [PRODUCT], are primary care practitioners required to use general 
health screening questionnaires that include questions about any of the fol-
lowing?
PROBE: By “required,” we mean that the health plan conveys the expecta-
tion that an action will be performed. Requirements that are not enforced 
may still be considered requirements.
a.  Mental health problems
b.  Alcohol problems
c.  Drug problems
d.  Smoking
.11 Under [PRODUCT], are primary care practitioners required to screen for 
smoking among at least some of their patients?
.1 Now I have some questions about the treatment of mental health, alco-
hol and drug problems, and smoking by primary care providers.
Under [PRODUCT] in [SITE], is there distribution of written guidelines specifi-
cally for primary care treatment of any of the following problems?
 
PROBE: By distribute, we mean electronic transmission or paper mailings.
PROBE: Guidelines are defined as standards used to guide providers based 
on accepted clinical treatment protocols for typical cases.
a.  Depression (MH)
b.  Anxiety (MH)
c.  Eating disorders (MH)
d.  Alcohol or drug abuse problems (SA)
e.  Smoking cessation (SM)
.18 [SKIP if 7.15 = no] For [PRODUCT], which, if any, of the following are 
given to primary care providers to encourage their adherence to these guide-
lines?
INTERVIEWER: ONLY ASK ABOUT GUIDELINES THAT ARE DISTRIBUTED 
FOR MENTAL HEALTH (MH), ALCOHOL OR DRUG ABUSE TREATMENT (SA), 
OR SMOKING CESSATION (SM) — ANY IN Q7.15 IS YES, OTHERWISE SKIP 
TO NEXT COLUMN.
a.  Financial incentives connected to guideline adherence
b.  Training about guidelines
c.  Feedback regarding their own performance relative to guidelines
d.  Feedback about guideline adherence by network providers in general